Do you want to read an article? Please log in or register.
Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg in patients age < 65 and ≥ 65 years: post hoc analysis of the AWARD-11 trial
Glycemic Control
Related content
Diabetes - GeneralType 2 Diabetes
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
Diabetes Care
Frias JP, Bonora E, Nevarez Ruiz L, Li YG, Yu Z, Milicevic Z, Malik R, Bethel MA, Cox DA
doi: 10.2337/dc20-1473
Diabetes - GeneralType 2 DiabetesGlycemic Control
Efficacy and Safety of Dulaglutide in Older Patients: A Post-hoc Analysis of the REWIND trial
J Clin Endocrinol Metab
Riddle MC, Gerstein HC, Xavier D, Cushman WC, Leiter LA, Raubenheimer PJ, Atisso CM, Raha S, Varnado OJ, Konig M, Lakshmanan M, Franek E
doi: 10.1210/clinem/dgab065
Type 2 Diabetes
Weight loss in patients with type 2 diabetes (T2D) mellitus receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: An AWARD-4 post-hoc analysis across baseline body mass index subgroups
Diabetes Obes Metab.
Fuechtenbusch M, Aberle J, Heitmann E, Nicolay C, Jung H
doi: 10.1111/dom.
Diabetes - GeneralGlycemic Control
Dulaglutide Treatment Results in Effective Glycemic Control in Latent Autoimmune Diabetes in Adults (LADA): A Post-Hoc Analysis of the AWARD-2, -4, and -5 Trials
Diabetes Obes Metab.
Pozzilli P, Leslie RD, Peters AL, Buzzetti R, Shankar SS, Milicevic Z, Pavo I, Lebrec J, Martin S, Schloot NC
doi: 10.1111/dom.13237.
Type 2 Diabetes
An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 mg and 4.5 mg
Diabetes Obes Metab
Pratley RE, Catarig AM, Lingvay I, Viljoen A, Paine A, Lawson J, Chubb B, Gorst-Rasmussen A, Miresashvili N
doi: 10.1111/dom.14497
Type 2 Diabetes
Efficacy and safety of semaglutide for type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials
J Clin Endocrinol Metab.
DeSouza C, Cariou B, Garg S, Lausvig N, Navarria A, Fonseca V
doi: 10.1210/clinem/dgz072.
Type 2 Diabetes
Effect of Once Weekly Dulaglutide versus Insulin Glargine in Patients with Type 2 Diabetes and Different Baseline Glycaemic Patterns: A Post-Hoc Analysis of the AWARD-2 Clinical Trial
Diabetes Obes Metab.
Giorgino F, Yu M, Haupt A, Milicevic Z, García-Pérez LE
doi: 10.1111/dom.13844.
COMMENTED
Further Publications
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a doubleblind, randomised withdrawal phase
★ 2
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol.
Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, Gu F, Auchus R, Leelawattana R, Lee EJ, Kim JH, Lacroix A, Laplanche A, O'Connell P, Tauchmanova L, Pedroncelli AM, Biller BMK, LINC 3 investigators
doi: 10.1016/S2213-8587(20)30240-0.
Type 2 Diabetes
Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: a patient-level, pooled analysis of the SUSTAIN 1-5 trials
Diabetes Obes Metab.
Aroda VR, Capehorn MS, Chaykin L, Frias JP, Lausvig NL, Macura S, Lüdemann J, Madsbad S, Rosenstock J, Tabak O, Tadayon S, Bain SC
doi: 10.1111/dom.13896.